{"abstract":"This notice, in accordance with 35 U.S.C. 209 and 37 CFR part 404, that the National Institutes of Health, Department of Health and Human Services, is contemplating the grant of an exclusive patent license to practice the inventions embodied in the following U.S. Patents and Patent Applications to Midissia Therapeutics (\"MIDISSIA\") located in San Francisco, California, USA.","action":"Notice.","agencies":[{"raw_name":"DEPARTMENT OF HEALTH AND HUMAN SERVICES","name":"Health and Human Services Department","id":221,"url":"https://www.federalregister.gov/agencies/health-and-human-services-department","json_url":"https://www.federalregister.gov/api/v1/agencies/221","parent_id":null,"slug":"health-and-human-services-department"},{"raw_name":"National Institutes of Health","name":"National Institutes of Health","id":353,"url":"https://www.federalregister.gov/agencies/national-institutes-of-health","json_url":"https://www.federalregister.gov/api/v1/agencies/353","parent_id":221,"slug":"national-institutes-of-health"}],"body_html_url":"https://www.federalregister.gov/documents/full_text/html/2016/03/22/2016-06374.html","cfr_references":[],"citation":"81 FR 15313","comment_url":null,"comments_close_on":"2016-04-06","correction_of":null,"corrections":[],"dates":"Only written comments and/or applications for a license which are received by the NIH Office of Technology Transfer on or before April 6, 2016 will be considered.","disposition_notes":null,"docket_ids":[],"dockets":[],"document_number":"2016-06374","effective_on":null,"end_page":15314,"executive_order_notes":null,"executive_order_number":null,"full_text_xml_url":"https://www.federalregister.gov/documents/full_text/xml/2016/03/22/2016-06374.xml","html_url":"https://www.federalregister.gov/documents/2016/03/22/2016-06374/prospective-grant-of-exclusive-license-development-and-commercialization-of-cancer-immunotherapy","images":{},"images_metadata":{},"json_url":"https://www.federalregister.gov/api/v1/documents/2016-06374?publication_date=2016-03-22","mods_url":"https://www.govinfo.gov/metadata/granule/FR-2016-03-22/2016-06374/mods.xml","not_received_for_publication":null,"page_length":2,"page_views":{"count":297,"last_updated":"2026-09-21 02:15:06 -0400"},"pdf_url":"https://www.govinfo.gov/content/pkg/FR-2016-03-22/pdf/2016-06374.pdf","presidential_document_number":null,"proclamation_number":null,"public_inspection_pdf_url":"https://public-inspection.federalregister.gov/2016-06374.pdf?1458564381","publication_date":"2016-03-22","raw_text_url":"https://www.federalregister.gov/documents/full_text/text/2016/03/22/2016-06374.txt","regulation_id_number_info":{},"regulation_id_numbers":[],"regulations_dot_gov_info":{"checked_regulationsdotgov_at":"2023-02-28T21:20:21Z"},"regulations_dot_gov_url":null,"significant":null,"signing_date":null,"start_page":15313,"subtype":null,"title":"Prospective Grant of Exclusive License: Development and Commercialization of Cancer Immunotherapy","toc_doc":"Development and Commercialization of Cancer Immunotherapy","toc_subject":"Exclusive License Approvals:","topics":[],"type":"Notice","volume":81}